Athena Vector Technology LLC

Athena Vector Technology LLC is at the forefront of material processing, dedicated to reshaping conventional norms and pioneering a safer, more cost-effective Indoor Residual Spray (IRS) insecticide. The company's mission is fueled by the vision to introduce community-based IRS solutions, to make a profound impact on malaria and other vector-borne diseases. Globally, there are a staggering 250 million malaria cases annually, resulting in over 600,000 fatalities, with a staggering 95% occurring in Africa. Sadly, this includes over 450,000 children under the age of 5.

The founder and CEO has spent the past decade deeply involved in the discovery, development, and market introduction of a revolutionary perlite active ingredient during his tenure with a previous employer. Recognizing an unprecedented opportunity, the decision was made to establish a startup that could expedite the delivery of this vital alternative insecticide with an intensified sense of urgency.

The perlite active ingredient in Aetna WP stands out for its complete lack of threat to human health or the environment. Remarkably, perlite, the same industrial mineral found in common items such as soil amendments, toothpaste, and cosmetics, is the key component of this groundbreaking insecticide.

Aetna WP's perlite active ingredient represents a paradigm shift, presenting a novel mode of action that holds the potential to revolutionize the battle against insecticide resistance, which is plaquing efforts to control this devasting disease.

Athena Vector Technology LLC is actively seeking investment funds to facilitate the delivery of this crucial product to communities in need at the most affordable prices possible. Over the next two years, the company's primary focus is on completing efficacy trials to support World Health Organization Pre-Qualification (WHO PQ) approval. This approval is essential for securing country-level approvals and subsequently launching the product commercially. Concurrently, Athena Vector Technology LLC will be establishing a pilot plant in Georgia to bolster product development efforts, solidifying its commitment to advancing global health outcomes.